X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
PTG-300 (rusfertide) is a hepcidin inhibitor, which is being evaluated in the Phase III clinical trial studies with patients for the treatment of Polycythemia Vera.
Lead Product(s): Rusfertide
Therapeutic Area: Oncology Product Name: PTG-300
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
The collaboration aims to support the development of PTG-300 (rusfertide) for the treatment of Polycythemia Vera. The protagonist will be responsible for research and development through the completion of the Phase 3 clinical trial and U.S. regulatory approval.
Lead Product(s): Rusfertide
Therapeutic Area: Oncology Product Name: PTG-300
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Undisclosed Upfront Cash: $300.0 million
Deal Type: Collaboration March 18, 2024
Details:
The collaboration aims to support the development of PTG-300 (rusfertide) for the treatment of Polycythemia Vera. The protagonist will be responsible for research and development through the completion of the Phase 3 clinical trial and U.S. regulatory approval.
Lead Product(s): Rusfertide
Therapeutic Area: Oncology Product Name: PTG-300
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Undisclosed Upfront Cash: $300.0 million
Deal Type: Collaboration January 31, 2024
Details:
The net proceeds intends to fund the continued clinical development and pre-commercialization activities associated with PTG-300 (rusfertide), an injectable hepcidin mimetic in development for the treatment of polycythemia vera and other blood disorders.
Lead Product(s): Rusfertide
Therapeutic Area: Oncology Product Name: PTG-300
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: J.P. Morgan Securities LLC
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 04, 2023
Details:
PTG-300 (rusfertide) is a hepcidin-mimetic that helps reduce iron availability to help achieve hematocrit control and decrease erythropoiesis in patients with polycythemia vera (PV) without the need for periodic therapeutic phlebotomy.
Lead Product(s): Rusfertide
Therapeutic Area: Oncology Product Name: PTG-300
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2023
Details:
The rasH2 signal also prompted a re-examination of the four cases of cancer observed across all rusfertide clinical trials involving over 160 patients, and a comprehensive review of the safety database, including cases of suspected unexpected serious adverse reactions (SUSAR).
Lead Product(s): Rusfertide
Therapeutic Area: Oncology Product Name: PTG-300
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2021
Details:
Protagonist's rusfertide clinical trials have been placed on clinical hold by the U.S. Food and Drug Administration (FDA). Protagonist is working closely with the FDA to determine next steps for the rusfertide development program.
Lead Product(s): Rusfertide
Therapeutic Area: Hematology Product Name: PTG-300
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2021
Details:
Rusfertide (PTG-300), an investigational, injectable hepcidin mimetic in a Phase 2 proof-of-concept clinical trial for polycythemia vera (PV), a Phase 2 study in PV subjects with high hematocrit levels, and a Phase 2 study for hereditary hemochromatosis.
Lead Product(s): Rusfertide
Therapeutic Area: Oncology Product Name: PTG-300
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2021
Details:
Rusfertide (PTG-300) is a novel injectable synthetic mimetic of the natural hormone hepcidin that offers greater potency, solubility, and stability, which may translate to better in vivo PK and PD characteristics in comparison to the natural hormone.
Lead Product(s): Rusfertide
Therapeutic Area: Oncology Product Name: PTG-300
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: J.P. Morgan Securities LLC
Deal Size: $132.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 18, 2021
Details:
Rusfertide (PTG-300) is an investigational, injectable hepcidin mimetic currently in a Phase 2 proof-of-concept clinical trial for polycythemia vera (PV), a Phase 2 study in PV subjects with high hematocrit levels, and a Phase 2 study for hereditary hemochromatosis.
Lead Product(s): Rusfertide
Therapeutic Area: Oncology Product Name: PTG-300
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2021
Details:
Protagonist-developed compounds currently include rusfertide (PTG-300), an investigational, injectable hepcidin mimetic in a Phase 2 proof-of-concept clinical trial for polycythemia vera, and a separate Phase 2 clinical study for hereditary hemochromatosis.
Lead Product(s): Rusfertide
Therapeutic Area: Oncology Product Name: PTG-300
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
